UK's Haleon cuts annual organic revenue growth forecast

British consumer healthcare firm Haleon (HLN.L) lowered its annual organic revenue growth forecast to 3.5% from a previous 4-6%, citing a subdued consumer environment and weaker performance in the United States. Although Q2 organic revenue growth of 3% slightly missed analyst expectations, the Sensodyne-maker reported first-half 2025 adjusted operating profit of £1.24 billion ($1.64 billion), exceeding consensus estimates of £1.22 billion, indicating a mixed financial picture with top-line pressures in North America offset by robust profitability.

Analysis

British consumer healthcare firm Haleon (HLN.L) has presented a mixed financial update, characterized by top-line pressure offset by strong profitability. The company revised its full-year organic revenue growth forecast downward to 3.5% from a previous 4-6% range, directly attributing the cut to a weaker consumer environment in the United States. This guidance revision is supported by the second quarter's performance, where organic revenue growth of 3.0% fell slightly short of the 3.3% consensus analyst expectation. Despite these revenue headwinds, Haleon demonstrated operational resilience by reporting a first-half adjusted operating profit of £1.24 billion, which surpassed the company-compiled consensus estimate of £1.22 billion. This suggests effective cost management or pricing power is currently compensating for the subdued demand in North America, a critical market for the company.

Key Decisions for Investors

• Investors should recalibrate near-term revenue growth expectations downward in line with the new 3.5% guidance, acknowledging the significant headwinds in the North American consumer market.
• Consider that Haleon's ability to beat profit forecasts despite missing revenue targets indicates strong operational efficiency, which could provide a cushion to margins if top-line weakness persists.
• Monitor future US consumer data and commentary from management on the North American outlook, as this region is the primary driver of the current forecast revision and a key variable for the stock's performance.